EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors

키워드

참고문헌 (30)

1. Siegel RL, "Cancer Statistics, 2017", CA Cancer J Clin, 67, pp.7~30 (2017)[DOI]
2. Spiro SG, "One hundred years of lung cancer", Am J Respir Crit Care Med, 172, pp.523~529 (2005)[DOI]
3. Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)[DOI]
4. Tan DS, "The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: status in 2016", J Thorac Oncol, 11, pp.946~963 (2016)[DOI]
5. 이대호, "Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned", Cancer Research and Treatment, 47(4), pp.549~554 (2015), 대한암학회[DOI]
6. Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)[DOI]
7. Do H, "High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies", BMC Cancer, 8, pp.142~ (2008)[DOI]
8. Roberts ME, "Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010", Thorax, 65(Suppl 2), pp.ii32~ii40 (2010)
9. Froudarakis ME, "Pleural effusion in lung cancer: more questions than answers", Respiration, 83, pp.367~376 (2012)[DOI]
10. Soh J, "Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer", Int J Cancer, 119, pp.2353~2358 (2006)[DOI]
11. Kimura H, "EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib", Br J Cancer, 95, pp.1390~1395 (2006)[DOI]
12. Wu SG, "Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma", Eur Respir J, 32, pp.924~930 (2008)[DOI]
13. Zhang X, "Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer", Lung Cancer, 60, pp.175~182 (2008)[DOI]
14. Liu Y, "A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients", J Exp Clin Cancer Res, 30, pp.111~ (2011)[DOI]
15. Jian G, "Prediction of epidermal growth factor receptor mutations in the plasma", pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer, 2010, pp.136, 1341~1347
16. Han HS, "EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases", Clin Lung Cancer, 12, pp.380~386 (2011)[DOI]
17. Han HS, "Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity", J Thorac Oncol, 7, pp.355~364 (2012)[DOI]
18. Yeo CD, "Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing", Lung Cancer, 81, pp.207~212 (2013)[DOI]
19. Liu D, "Malignant pleural effusion supernatants are substitutes for metastatic pleural tumor tissues in EGFR mutation test in patients with advanced lung adenocarcinoma", PLoS One, 9, pp.e89946~ (2014)[DOI]
20. Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)[DOI]
21. Japan Lung Cancer Society, "Classification of lung cancer", pp.49~52 (2000)
22. Masago K, "Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer", Mol Clin Oncol, 3, pp.415~419 (2015)[DOI]
23. Fujita A, "Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer : cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support", Chest, 119, pp.340~343 (2001)[DOI]
24. Wang TF, "Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptormutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment", Asia Pac J Clin Oncol, 13, pp.304~313 (2017)[DOI]
25. Masago K, "Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-smallcell lung cancer with pleural effusion", Clin Lung Cancer, 12, pp.307~312 (2011)[DOI]
26. Chen SF, "Pulmonary adenocarcinoma in malignant pleural effusion enriches cancer stem cell properties during metastatic cascade", PLoS One, 8, pp.e54659~ (2013)[DOI]
27. Liotta LA, "Anoikis: cancer and the homeless cell", Nature, 430, pp.973~974 (2004)[DOI]
28. Cheng D, "Vascular endothelial growth factor level correlates with transforming growth factor-beta isoform levels in pleural effusions", Chest, 118, pp.1747~1753 (2000)[DOI]
29. Sikora JJ, "Immunosuppressive mechanisms in the microenvironment of malignant pleural effusions", Cancer Detect Prev, 28, pp.325~330 (2004)[DOI]
30. Singh A, "EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer", Oncogene, 29, pp.4741~4751 (2010)[DOI]

관련 논문AI추천